Ensign Peak Advisors, Inc Halozyme Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $51.2 Billion
- Q1 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 42,668 shares of HALO stock, worth $2.94 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,668
Previous 42,668
-0.0%
Holding current value
$2.94 Million
Previous $2.04 Million
33.5%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding HALO
# of Institutions
605Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.22 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$845 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$409 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$239 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$234 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.61B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...